Ligand Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell LGND and other ETFs, options, and stocks.

About LGND

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. 

CEO
Todd Christopher Davis
CEOTodd Christopher Davis
Employees
47
Employees47
Headquarters
Jupiter, Florida
HeadquartersJupiter, Florida
Founded
1987
Founded1987
Employees
47
Employees47

LGND Key Statistics

Market cap
4.01B
Market cap4.01B
Price-Earnings ratio
34.07
Price-Earnings ratio34.07
Dividend yield
Dividend yield
Average volume
176.22K
Average volume176.22K
High today
$210.46
High today$210.46
Low today
$199.61
Low today$199.61
Open price
$206.43
Open price$206.43
Volume
108.66K
Volume108.66K
52 Week high
$212.49
52 Week high$212.49
52 Week low
$93.58
52 Week low$93.58

Stock Snapshot

With a market cap of 4.01B, Ligand Pharmaceuticals(LGND) trades at $201.23. The stock has a price-to-earnings ratio of 34.07.

During the trading session on 2026-03-05, Ligand Pharmaceuticals(LGND) shares reached a daily high of $210.46 and a low of $199.61. At a current price of $201.23, the stock is +0.8% higher than the low and still -4.4% under the high.

Trading volume for Ligand Pharmaceuticals(LGND) stock has reached 108.66K, versus its average volume of 176.22K.

Over the past 52 weeks, Ligand Pharmaceuticals(LGND) stock has traded between a high of $212.49 and a low of $93.58.

Over the past 52 weeks, Ligand Pharmaceuticals(LGND) stock has traded between a high of $212.49 and a low of $93.58.

LGND News

Simply Wall St 18h
Ligand Pharmaceuticals Is Up 8.1% After Swinging to Profit and Filing New Equity Shelf - What's Changed

In late February 2026, Ligand Pharmaceuticals reported a sharp improvement in fourth-quarter and full-year 2025 results, turning prior-year losses into net inco...

Ligand Pharmaceuticals Is Up 8.1% After Swinging to Profit and Filing New Equity Shelf - What's Changed
Simply Wall St 6d
Assessing Ligand Pharmaceuticals Valuation After Strong One Year Returns And Elevated P/E Ratio

Advertisement Event context and recent share performance Ligand Pharmaceuticals (LGND) has been drawing attention after a period of mixed share performance, w...

Assessing Ligand Pharmaceuticals Valuation After Strong One Year Returns And Elevated P/E Ratio
The Motley Fool 7d
Ligand Pharma Earnings Call Transcript

Image source: The Motley Fool. Thursday, February 26, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Todd Davis Chief Financial Officer — Oct...

Ligand Pharma Earnings Call Transcript

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own LGND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.